These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37252463)

  • 1. Efficacy of Hydroxyurea in Transfusion-Dependent Major β-Thalassemia Patients: A Meta-Analysis.
    Hatamleh MI; Chenna VSH; Contractor H; Krishna Mohan GV; Tirumandyam G; Dammas N; Khan MW; Hirani S
    Cureus; 2023 Apr; 15(4):e38135. PubMed ID: 37252463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004450. PubMed ID: 23963793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Hydroxyurea as Adjuvant Therapy in Pediatric Patients of Transfusion-Dependent Beta-Thalassemia Major at Zhob, Balochistan.
    Akram S; Khan Khattak SA; Khan MA
    Cureus; 2022 Jul; 14(7):e26691. PubMed ID: 35959173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyurea for nontransfusion-dependent β-thalassemia: A systematic review and meta-analysis.
    Algiraigri AH; Wright NAM; Paolucci EO; Kassam A
    Hematol Oncol Stem Cell Ther; 2017 Sep; 10(3):116-125. PubMed ID: 28408107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyurea (hydroxycarbamide) for transfusion-dependent β-thalassaemia.
    Ansari SH; Lassi ZS; Khowaja SM; Adil SO; Shamsi TS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012064. PubMed ID: 30882896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea for lifelong transfusion-dependent β-thalassemia: A meta-analysis.
    Algiraigri AH; Wright NAM; Paolucci EO; Kassam A
    Pediatr Hematol Oncol; 2017 Nov; 34(8):435-448. PubMed ID: 29337597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea for hemoglobin E/β-thalassemia: a systematic review and meta-analysis.
    Algiraigri AH; Kassam A
    Int J Hematol; 2017 Dec; 106(6):748-756. PubMed ID: 28786080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral deferiprone for iron chelation in people with thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Chowdhury O; Gooding S; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004839. PubMed ID: 23966105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of oral hydroxyurea in transfusion-dependent β-thalassaemia: a protocol for randomised double-blind controlled clinical trial.
    Yasara N; Wickramarathne N; Mettananda C; Manamperi A; Premawardhena A; Mettananda S
    BMJ Open; 2020 Oct; 10(10):e041958. PubMed ID: 33109679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to hydroxyurea therapy in beta-thalassemia.
    Koren A; Levin C; Dgany O; Kransnov T; Elhasid R; Zalman L; Palmor H; Tamary H
    Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran.
    Karimi M; Darzi H; Yavarian M
    J Pediatr Hematol Oncol; 2005 Jul; 27(7):380-5. PubMed ID: 16012328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogen-reduced platelets for the prevention of bleeding.
    Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
    Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT).
    Ansari SH; Shamsi TS; Siddiqui FJ; Irfan M; Perveen K; Farzana T; Panjwani VK; Yousuf A; Mehboob T
    J Pediatr Hematol Oncol; 2007 Nov; 29(11):743-6. PubMed ID: 17984691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 2 Randomized Controlled Trial of Single-Agent Hydroxyurea Versus Thalidomide Among Adult Transfusion Dependent β Thalassemia Patients.
    Bhattacharjee U; Khadwal A; Shafiq N; Lad D; Sharma P; Das R; Shukla P; Jain A; Prakash G; Malhotra P
    Indian J Hematol Blood Transfus; 2023 Apr; 39(2):266-275. PubMed ID: 36620489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
    Fortin PM; Hopewell S; Estcourt LJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012082. PubMed ID: 30067867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Literature Review of the Burden of Disease and Treatment for Transfusion-dependent β-Thalassemia.
    Betts M; Flight PA; Paramore LC; Tian L; Milenković D; Sheth S
    Clin Ther; 2020 Feb; 42(2):322-337.e2. PubMed ID: 31882227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
    Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    Wang WC; Dwan K
    Cochrane Database Syst Rev; 2013 Nov; (11):CD003146. PubMed ID: 24226646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
    Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC
    Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.